JGC
PBYI icon

J. Goldman & Co’s Puma Biotechnology PBYI Stock Holding History

J. Goldman & Co’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-238,617
Closed -$2.45M – 505
2020
Q4 		$2.45M Buy
+238,617
New +$2.42M 0.12% 177
2018
Q1 		– Sell
-31,829
Closed -$3.15M – 413
2017
Q4 		$3.15M Buy
31,829
+15,429
+94% +$1.73M 0.17% 155
2017
Q3 		$1.96M Buy
+16,400
New +$1.53M 0.1% 196
2017
Q2 		– Sell
-3,102
Closed -$115K – 388
2017
Q1 		$115K Buy
+3,102
New +$113K 0.01% 308
2016
Q4 		– Sell
-49,500
Closed -$3.32M – 363
2016
Q3 		$3.32M Buy
+49,500
New +$2.5M 0.19% 148

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

J. Goldman & Co's PBYI Position: Q1 2021 in Review

J. Goldman & Co sold out of Puma Biotechnology (PBYI) in Q1 2021, closing a stake of 238,617 shares — an estimated $2.45M sold.

J. Goldman & Co first reported a position in PBYI in Q3 2016 and held it in 5 quarters. The position peaked at $3.32M in Q3 2016. 118 funds tracked by Wall St. Rank hold PBYI as of Q1 2021.

  • J. Goldman & Co reported no remaining Puma Biotechnology position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 238,617 Puma Biotechnology shares in Q1 2021, an estimated $2.45M.
  • J. Goldman & Co first reported a position in Puma Biotechnology in Q3 2016 and held it in 5 quarters.
  • J. Goldman & Co's Puma Biotechnology position peaked at $3.32M in Q3 2016.
  • 118 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.